Haemorrhagic complications tracheotomy in the era of COVID-19 – a retrospective study

Czech version

Authors: L. Čábalová ^1,2 ; J. Šulhin ¹ ; Karol Zeleník ^1,2 ; Pavel Komínek ^1,2
Authors‘ workplace: Klinika otorinolaryngologie a chirurgie hlavy a krku, FN Ostrava ¹; Katedra kraniofaciálních oborů, Lékařská fakulta OU, Ostrava ²
Published in: Otorinolaryngol Foniatr, 74, 2025, No. 3, pp. 215-222.
Category: Original Article
doi: https://doi.org/10.48095/ccorl2025215

Overview

Introduction: New type of coronavirus SARS-CoV-2 (COVID-19) infection usually manifests as an upper respiratory tract infection. Some patients develop pneumonia, which can progress into serious respiratory insufficiency with the need of artificial pulmonary ventilation (APV). In case of a long-term APV, it is necessary to perform tracheotomy. Since COVID-19 infection causes thrombophilia and patients are treated with anticoagulants, these patients might be in greater risk of postoperative complications, mainly bleeding, after tracheotomy. Aims: To assess the frequency of severe postoperative bleeding after tracheotomy in COVID-19 positive patients with prolonged orotracheal intubation and to identify risk factors of severe bleeding in patients after tracheotomy. Materials and methodology: A retrospective analysis of patients with tracheostomy due to prolonged APV was performed between 2020–2022. The data were obtained from the hospital information system and were statistically analyzed. Results: Out of a total of 146 patients, bleeding requiring surgical revision in the intensive care unit or in the operating room occurred in 30 (20.5%) patients. Among these patients, a COVID-19 PCR test was positive in 20/30 (66.7%) and negative in 10/30 (33.3%) patients. From all of the analyzed factors, the only factor with statistical significance was a therapeutical dose of anticoagulants (P = 0.012). Ocurrence of bleeding was not influenced by the type of surgery, transsection of the thyroid gland isthmus, setting of the surgery, or qualification of the surgeon. Conclusion: Results of this retrospective study did not show a higher risk of bleeding after tracheotomy in COVID-19 positive patients compared to COVID-19 negative patients. However, the multiple logistic regression model suggested that COVID-19 infection could increase the risk. Therapeutical anticoagulant treatment is a clear risk factor of severe postoperative bleeding after tracheotomy.

Keywords:

COVID-19 pneumonia – tracheotomy – hemorrhagic complications – complications of tracheotomy

Sources

1. Kessler C, Stricker H, Demundo D et al. Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis. J Thromb Thrombolysis 2020; 50 (4): 833–836. Doi: 10.1007/s11239-020-02244-y.

2. Musoke N, BryanLo K, Albano J et al. Anticoagulation and bleeding risk in patients with COVID-19. Thromb Res 2020; 196 : 227–230. Doi: 10.1016/j.thromres.2020.08.035.

3. Lopes RD, Silva PGMBe, Furtado RHMF et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): An open-label, multicentre, randomised, controlled trial. Lancet 2021; 397 (10291): 2253–2263. Doi: 10.1016/S0140-6736 (21) 01203-4.

4. Pilia E, Belletti A, Fresilli S et al. The effect of heparin full-dose anticoagulation on survival of hospitalized, non-critically ill COVID-19 patients: A meta-analysis of high quality studies. Lung 2023; 201 (2): 135–147. Doi: 10.1007/s00408-023-00599-6.

5. Wendy L, Maureen M, Lauzier F et al. Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients, Crit Care Med 2015; 43 (2): 401–410. Doi: 10.1097/CCM.0000000000000713.

6. Simon M, Metschke M, Braune SA et al. Death after percutaneous dilatational tracheostomy: a systematic review and analysis of risk factors. Crit Care 2013; 17 (5): R258. Doi: 10.1186/cc13085.

7. Beiderlinden M, Eikermann M, Lehmnann et al. Risk factors associated with bleeding during and after percutaneous dilational tracheostomy. Anaesthesia 2007; 62 (4): 342–346. Doi: 10.1111/j.1365-2044.2007.04979.x.

8. Yang W, Kandula S, Huynh M et al. Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis. Lancet Infect Dis 2021; 21 (2): 203–212. Doi: 10.1016/S1473 -⁠ 3099 (20) 30769-6.

9. Romero CM, Cornejo R, Tobar E et al. Fiberoptic bronchoscopyassisted percutaneous tracheostomy is safe in obese critically ill patients: a prospective and comparative study. Rev Bras Ter Intensiva 2015; 27 (2): 119–124. Doi: 10.5935/0103-507X.20150022.

10. Mansharamani NG, Koziel H, Garland R et al. Safety of bedside percutaneous dilatational tracheostomy in obese patients in the ICU. Chest 2000; 117 (5): 1426–1429. Doi: 10.1378/chest.117.5.1426.

11. Higgins KM, Punthakee X. Meta-analysis comparison of open versus percutaneous tracheostomy. Laryngoscope 2007; 117 (3): 447–454. Doi: 10.1097/01.mlg.0000251585.31778.c9.

12. Nadkarni GN, Lala A, Bagiella E et al. Anticoagulation, bleeding, mortality and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol 2020; 76 (16): 1815–1826. Doi: 10.1016/j.jacc.2020.08.041.

13. Levi M, Thachil J, Iba T et al. Coagulation abnormalities and thrombosis in patients with COVID--19. Lancet Haematol 2020; 7 (6): e438–e440. Doi: 10.1016/S2352-3026 (20) 30145-9.

14. Boonyawat K, Chantrathammachart P, Numthavaj P et al. Incidence of thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Thromb J 2020; 18 (1): 34. Doi: 10.1186/s12959-020-00248-5.

15. Greinacher A, Selleng K. Thrombocytopenia in the intensive care unit patient. Hematology Am Soc Hematol Educ Program 2010; 2010 : 135–143. Doi: 10.1182/asheducation-2010.1.135.

16. Díaz-Regañón G, Miñambres E, Ruiz A et al. Safety and complications of percutaneous tracheostomy in a cohort of 800 mixed ICU patients. Anaesthesia 2008; 63 (11): 1198–1203. Doi: 10.1111/j.1365-2044.2008.05606.x.

17. Deppe AC, Kuhn E, Scherner M et al. Coagulation disorders do not increase the risk for bleeding during percutaneous dilatational tracheotomy. Thorac Cardiovasc Surg 2013; 61 (3): 234–239. Doi: 10.1055/s-0032-1322608.

18. Spyropoulos AC, Goldin M, Giannis D et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high--risk hospitalized patients with COVID-19: The HEP-COVID randomized clinical trial. JAMA Intern Med 2021; 181 (12): 1612–1620. Doi: 10.1001/jamainternmed.2021.6203.

19. Sholzberg M, Tang GH, Rahhal H et al. Heparin for moderately ill patients with Covid-19. medRxiv 2021; 12 : 2021. Doi: 10.1101/2021. 07.08.21259351.

20. Ackermann M, Stijn EV, Kuehnel M et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020; 383 (2): 120–128. Doi: 10.1056/NEJMoa2015432.

21. Cuker A, Tseng EK, Nieuwlaat R et al. American society of hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv 2021; 5 (3): 872–888. Doi: 10.1182/blood advances.2020003763.

22. Pavlov V, Beylerli O, Gareev I et al. COVID--19-related intracerebral hemorrhage. Front Aging Neurosci 2020; 22 : 12. Doi: 10.3389/fnagi. 2020.600172.